| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and other | 200 | 131 | 375 | 357 |
| Research and development | 7,450 | 7,430 | 8,351 | 8,130 |
| General and administrative | 7,070 | 7,480 | 9,335 | 7,028 |
| Total operating costs and expenses | 14,520 | 14,910 | 17,686 | 15,158 |
| Foreign currency transaction gain (loss) | - | 3,640 | 1,898 | 2,760 |
| Loss from operations | -14,320 | -14,779 | -17,311 | -14,801 |
| Change in fair value of derivative liabilities | -3,332 | 724 | 1,280 | -1,590 |
| Change in fair value of share payable | -118 | -240 | -23 | 70 |
| Change in fair value of convertible notes | -15 | 2,392 | 3,697 | 3,087 |
| Loss from extinguishment of debt | -4,004 | -4,516 | -7,282 | -6,820 |
| Loss from issuance of debt | -1,611 | -773 | - | - |
| Interest expense | 2,621 | 1,826 | 1,602 | 2,080 |
| Foreign currency transaction gain (loss) | -808 | - | - | - |
| Total other expense | -12,509 | -599 | -2,032 | -4,573 |
| Net loss | -26,829 | -15,378 | -19,343 | -19,374 |
| Deemed dividend related to warrant modifications | 353 | 560 | 265 | 132 |
| Net loss attributable to common stockholders | -27,182 | -15,938 | -19,608 | -19,506 |
| Foreign currency translation adjustment | -632 | 3,248 | 1,644 | - |
| Total comprehensive loss | -26,550 | -19,186 | -21,252 | - |
| Earnings per share, basic | -0.02 | -0.01 | -0.01 | -0.02 |
| Earnings per share, diluted | -0.02 | -0.01 | -0.01 | -0.02 |
| Weighted average number of shares outstanding, basic | 1,492,079 | 1,438,198 | 1,359,496 | 1,258,532 |
| Weighted average number of shares outstanding, diluted | 1,492,079 | 1,438,198 | 1,359,496 | 1,258,532 |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)